Top Boston, MA Health Tech Companies With Best Stability & Growth (376)

Investor Backing & Capital Strength: Feedback suggests fresh capital from a recent Series C is being directed to scale operations and expand AI use cases. Multiple reports of funding supporting acquisitions and platform build-out indicate solid financial runway.

Product Line Growth: Acquiring ZignaAI and launching a Payment Integrity suite expand offerings beyond utilization management into claims accuracy and coding validation. The platform’s AI is also described as extending from outpatient UM into inpatient care and policy management.

Strategic Partnerships: New and expanded payer partnerships (e.g., HealthPartners, Medical Mutual, Geisinger) and a nationwide Humana deployment point to broader plan adoption. Company communications cite multiple new deals and rising prior-authorization submissions, signaling growing commercial traction.

Strong Revenue Growth: Company announcements indicate it surpassed $100M in contracted annual recurring revenue by the end of 2025. This milestone, alongside repeated inclusion on high‑growth company lists, points to accelerating top‑line momentum.

Investor Backing & Capital Strength: A $65M growth investment led by Lead Edge Capital was disclosed to accelerate AI agent capabilities and expansion. This fresh capital provides additional resources to scale product and distribution.

Strong Market Position & Advantage: Artera was named #1 Best in KLAS for Patient Communications in 2026, reinforcing adoption and satisfaction signals in its category. Disclosures cite 1,000+ healthcare organizations and billions of annual patient communications, evidencing broad footprint.

Strong Revenue Growth: Revenue continues to rise at a double‑digit pace year over year with acceleration into year‑end. Management reaffirmed guidance for another year of meaningful top‑line expansion.

Market Expansion: The customer base and analysis volumes increased to record levels, and two large U.S. integrated health systems are expected to add substantial annual throughput as implementations ramp in the second half of 2026. Net dollar retention improved, indicating deeper adoption within existing institutions.

Strategic Partnerships: Collaborations with leading cancer centers and biopharma (e.g., MSK‑ACCESS powered with SOPHiA DDM, AstraZeneca, MD Anderson) are expanding product adoption and opening key U.S. channels. These alliances signal validation of the platform and support growth in high‑value applications like liquid biopsy.

Strong Revenue Growth: Results indicate net sales increased year over year and management signaled continued growth ahead. Active customers and spend per customer also rose, supporting resumed top‑line momentum.

Profitability: Disclosures show adjusted EBITDA and margins expanded, reflecting improving operating leverage. This points to better unit economics as scale increases.

Healthy Cash Flow: The company generated record free cash flow in the most recent year. Strong cash generation supports reinvestment in services, membership, and healthcare initiatives.

Investor Backing & Capital Strength: Fresh capital includes a $50M Series D on April 9, 2026 led by Boehringer Ingelheim and a 2025 Series C with Dassault Systèmes/Medidata to fund commercialization and platform scaling. Feedback suggests these transactions reflect strong external confidence and provide runway to advance regulatory and launch efforts.

Product Line Growth: Multiple FDA authorizations (Rejoyn in 2024; CT‑132 in 2025), positive Phase 3 data for CT‑155, and acquisition of Better Therapeutics’ assets expand the portfolio across psychiatry, neurology, and cardiometabolic conditions. A 2026 Ultrahuman partnership further extends migraine technology into adjacent offerings.

Strategic Partnerships: Multi‑year collaborations with Boehringer Ingelheim and Otsuka, plus ecosystem ties with Dassault Systèmes/Medidata and Ultrahuman, underpin development and prospective commercialization. These alliances distribute risk and provide capabilities and channels that many peers lack.

Strong Revenue Growth: Reported total net revenue rose from $693.4 million in 2024 to about $1.27 billion in 2025, with Q4 2025 also showing strong year‑over‑year growth. Management guides 2026 revenue to roughly $1.59 billion, indicating continued expansion.

Customer Loyalty & Retention: Disclosed net revenue retention of approximately 126% and total remaining contract value exceeding $1.1 billion signal expanding multi‑year demand. These metrics indicate existing customers are increasing spend and extending commitments.

Strategic Partnerships: Multi‑year collaborations with major pharmas and health systems—including a three‑year, $200 million data/modeling agreement with AstraZeneca/Pathos and an expanded Merck collaboration—support growth in data licensing and AI applications. Partnerships with top‑tier sponsors evidence strong demand for the platform.

Investor Backing & Capital Strength: Feedback suggests substantial late-stage funding from prominent investors and a rising valuation underpin resources for expansion and product development. These signals point to strong capital availability to support scaling plans.

Strong Market Position & Advantage: Feedback suggests adoption by many top MedTech companies and industry recognition indicate an advantaged position within its defined niche. Case studies and enterprise expansions further reinforce perceived market traction.

Innovation-Driven Growth: Feedback suggests ongoing AI feature releases, product enhancements, and ecosystem integrations are catalyzing customer adoption. These moves demonstrate a roadmap focused on modernizing MedTech commercial workflows.

Strong Revenue Growth: Company disclosures indicate recurring revenue rose significantly in recent periods and the customer base expanded from thousands to many thousands across North America. Growth is further evidenced by enterprise adoption and continued product and market launches.

Market Expansion: The company has moved beyond offices into hospitality, multi-family, factories, warehouses, gyms, and airport lounges, opened a new direct market, and entered the U.K. and Ireland. These steps show widening geographic reach and vertical diversification.

Profitability: Leadership states the business achieved profitability and expects EBITDA positivity, implying improving unit economics alongside scale. This profitability is presented alongside continued hiring and product development.

Strong Revenue Growth: Recent disclosures indicate 2025 revenue surpassed $750 million with 45% year‑over‑year growth, with outlook commentary noting sales approaching $1 billion in 2026. This trajectory reflects accelerating scale across the business.

Profitability: The company reports eight consecutive years of profitability. Business press coverage reinforces this sustained profitable profile alongside rapid scaling.

Diversified Revenue Streams: Management emphasizes health services and media as incremental growth vectors, with third‑party coverage noting strong 2025 growth in both areas. Babylist Health’s first‑year traction (including large volumes of insurance‑covered breast pump shipments) underscores revenue diversity beyond core registry commerce.

Market Expansion: Headcount and office disclosures show an expansion from 35+ to 40+ offices, alongside new capacity such as the Hyderabad Operations Center. These moves indicate a broader global presence to meet demand.

Strong Hiring & Retention: Recent materials cite 2,783 new hires in 2024 and over 2,850 promotions, with labor‑market analytics indicating year‑over‑year headcount growth through 2025. These suggest sustained talent investment and scaling.

Innovation-Driven Growth: Creation of a dedicated Platform & Products unit and scaling of ZAIDYN/Max.AI signal a push toward scalable, AI‑enabled offerings. Acquisitions such as Digital Additive (2024) and Torrent Consulting (2025) further broaden Salesforce and AI capabilities.

Investor Backing & Capital Strength: Recent late-stage funding rounds and a higher valuation are presented as clear signals of substantial capital support and investor confidence. The company indicates plans to deploy this capital toward team growth and product development across core markets.

Strong Revenue Growth: Management reports crossing a major ARR milestone with multiple years of rapid top-line expansion. Consistent year-over-year acceleration is highlighted alongside continued scaling plans.

Market Expansion: The business is extending beyond housing into healthcare and signaling international ambitions. New office hubs and active hiring across functions support broader geographic and vertical reach.

Strong Revenue Growth: 2025 results show total revenue increased meaningfully year over year, with software higher and drug‑discovery contributions expanding. Management also guides continued expansion into 2026 as measured by software ACV.

Strategic Partnerships: Large, multi‑target collaborations (e.g., with Novartis) and integrations with leading pharmas (e.g., Lilly) reinforce commercial traction and ecosystem reach. These relationships support both recurring software usage and potential milestone‑driven upside.

Future-Ready Strategy: Accelerating the shift from on‑premise to hosted licensing is intended to make revenue more predictable and better align recognition with contract value. 2026 priorities emphasize platform scaling, new offerings like predictive toxicology, and deeper partner integrations.

Product Line Growth: Reports indicate the platform has broadened through acquisitions (e.g., Verosint, SecureLink, FairWarning) and continued feature releases in areas like passwordless and ITDR. These moves expand capabilities across third‑party/privileged access, privacy monitoring, and risk signaling.

Innovation-Driven Growth: Evidence suggests active investment in AI/agent access controls and identity threat detection, with ongoing product shipping into 2026. This cadence points to a roadmap focused on emerging identity risks and frictionless clinical workflows.

Strong Market Position & Advantage: Independent recognition such as consecutive Best in KLAS wins for Access Management and deep EHR workflow integrations reinforce a defensible position in healthcare access management. This standing supports upsell and cross‑sell within existing health‑system accounts.

Investor Backing & Capital Strength: Recent financing at a sharply higher valuation, including strategic healthcare investors, signals strong external confidence and ample resources for scale. Management’s stated expansion plans and partnerships indicate capital is being deployed toward R&D and international growth.

Strong Revenue Growth: Company-reported bookings grew significantly year over year and aligned third‑party estimates indicate an exit run rate around the billion‑dollar level. These signals point to robust top‑line momentum heading into 2026.

Healthy Cash Flow: Management reported operating cash‑flow positivity in 2025. Positive cash generation alongside growth supports increased operating flexibility.

Investor Backing & Capital Strength: A new funding round in January 2025 is cited across trackers, providing runway to support expansion and product buildout. This fresh capital aligns with continued platform promotion and broader commercial engagement.

Market Expansion: The platform reports engagement with more than 4,250 covered entities across all 50 states, indicating broad provider-side reach. Such breadth supports ongoing adoption of verification and compliance workflows.

Future-Ready Strategy: Manufacturers are newly requiring claims-level data submissions in 2026, which increases demand for claim verification and good faith inquiry tools Kalderos offers. Product launches like Discount Hub position the company to address these data and workflow needs.

Profitability: Adjusted EBITDA of $70.4M in 2025 with a 29% margin and Q4 2025 margin at 29% indicate disciplined cost control despite softer revenue. Management’s 2026 guide still anticipates mid‑20s margins, underscoring ongoing profit focus.

Healthy Cash Flow: Cash flow from operations totaled $53.8M in 2025 with positive unlevered free cash flow. This cash generation provides flexibility while the company works to stabilize growth.

Future-Ready Strategy: Management emphasizes improving retention, upsell/cross‑sell, and product integration, alongside continued product innovation and ecosystem alignment. Recognition such as Databricks’ 2024 Healthcare & Life Sciences Partner of the Year signals integration momentum in modern data stacks.

Strong Revenue Growth: Recent disclosures cite surpassing $1 billion in 2023 and approximately $1.1 billion in 2024, with double‑digit momentum into the first half of 2024. These signals point to sustained top‑line expansion beyond the initial $1B milestone.

Product Line Growth: Frequent IRIS releases through 2025 (e.g., 2025.3) and new offerings such as IntelliCare EHR, Payer Connector, and HealthShare AI Assistant indicate an expanding portfolio. Added capabilities like vector support and enhanced partitioning underscore continued product investment.

Strong Brand Reputation: Multiple 2025–2026 Best in KLAS awards and IDC MarketScape leadership placements reinforce category strength in healthcare. Repeated honors for Acute Care EHR in Asia/Oceania/France and Shared Care Records in Europe suggest durable customer trust.

Market Expansion: Adoption is cited across 150+ hospital and health‑system sites and more than 300,000 frontline staff, with system‑wide scale referenced at large providers. The acquisition by Ascend Learning positions Laudio within a broader workforce solutions portfolio, indicating distribution leverage for further reach.

Product Line Growth: The launch of AI‑powered Performance Insights and the addition of a patient rounding module expand the platform’s scope for frontline leader workflows. These releases show continued feature velocity post‑acquisition.

Innovation-Driven Growth: Recognition on Fast Company’s Most Innovative Companies list and ongoing research programs with AONL and ASHHRA highlight emphasis on AI‑enabled capabilities and evidence generation. Case studies reporting retention improvements and material savings underscore outcomes linked to the innovative approach.